A Multicenter, Randomized, Placebo-controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency
Latest Information Update: 03 Nov 2023
At a glance
- Drugs Sebelipase alfa (Primary)
- Indications Cholesterol ester storage disease
- Focus Registrational; Therapeutic Use
- Acronyms ARISE
- Sponsors Alexion AstraZeneca Rare Disease
- 10 Nov 2021 final results of the phase 3 randomized ARISE study of sebelipase alfa published in the Journal of Hepatology
- 16 Dec 2019 Status changed from active, no longer recruiting to completed.
- 24 Oct 2017 Long-term results of the study assessing Sebelipase Alfa over 100 weeks adults and children with Lysosomal Acid Lipase Deficiency, presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases